FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233745237> ?p ?o ?g. }

• W4233745237 endingPage "5" @default.
• W4233745237 startingPage "4" @default.
• W4233745237 abstract "Alimentary Pharmacology & TherapeuticsVolume 51, Issue 1 p. 4-5 EDITORIALFree Access A Message from the Editors First published: 18 December 2019 https://doi.org/10.1111/apt.15602AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Jon Rhodes and Colin Howden, Co-Editors Welcome to the first edition of AP&T for 2020. The journal has been in continuous publication since 1987 and we are celebrating the landmark publication of our 50th volume during 2019 with this special edition. We highlight 10 of the most impactful papers that we have published, each accompanied by a commentary from a relevant expert. You will find these towards the end of this edition. We recently welcomed three new Associate Editors. Professor Gideon Hirschfeld has taken over from Professor Peter Hayes for general liver-related papers, Professor Richard Gearry has replaced Professor Ailsa Hart with responsibility for IBD-related papers and Professor Stephen Ryder has replaced Professor Stephen Harrison for liver-related papers. The increasing prestige of the journal is reflected in the most recent increase in our impact factor (IF); during 2019, our 2-year IF increased from 7.357 to 7.731 ranking AP&T in 11th place among 84 journals in gastroenterology and hepatology. The 10 papers published during 2018 that were the most highly cited during 20191-10 included such diverse topics as the epidemiology of Helicobacter pylori infection, the intestinal mirobiome and dysbiosis, biologic agents for IBD and evolving treatments for chronic viral hepatitis. Another relevant measure of AP&T’s success is the number of times that our papers are downloaded. During 2019, the number of individual downloads via Wiley Online Library (WOL) was 1,763,117 representing an increase of 17% over the same period for the preceding year. The 10 most frequently downloaded papers on WOL, published between 1st October 2018 and 30th September 2019, covered a variety of topics including prebiotics and probiotics for IBS, potassium-competitive acid blockers in reflux disease, dietary FODMAPs, the microbiome (inevitably) and the cholestatic consequences of bodybuilding supplements.11-20 These 10 papers will be free-access for the next 12 months. AP&T continues to attract high-quality research across a broad spectrum of digestive and liver issues. We thank the Associate Editors, our International Editorial Advisory Board and all those who review papers for us. The enduring success of the journal is due largely to their efforts. Our mission statement is ‘AP&T aims to publish high quality, clinically relevant original research and review articles in gastroenterology and hepatology’. As always, we would be pleased to receive your comments about the journal and any suggestions on how we can improve. REFERENCES 1Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47: 868– 876. 2McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL. Review article: the gut microbiome in inflammatory bowel disease—avenues for microbial management. Aliment Pharmacol Ther. 2018; 47: 26– 42. 3Le Bastard Q, Al-Ghalith GA, Grégoire M, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther. 2018; 47: 332– 345. 4Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018; 47: 356– 363. 5Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018; 47: 421– 431. 6Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018; 47: 192– 202. 7Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018; 47: 454– 465. 8Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018; 47: 906– 912. 9Mak L-Y, Wong DK-H, Cheung K-S, Seto W-K, Lai C-L, Yuen M-F. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018; 47: 43– 54. 10Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018; 47: 162– 175. 11Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018; 48: 1044– 1060. 12O’Grady J, O’Connor EM, Shanahan F. Review article: dietary fibre in the era of microbiome science. Aliment Pharmacol Ther. 2019; 49: 506– 515. 13Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019; 49: 140– 146. 14Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther. 2019; 49: 1134– 1172. 15Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019; 50: 289– 294. 16Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019; 49: 864– 872. 17Mitchell H, Porter J, Gibson PR, Barrett J, Garg M. Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome—directions for future research. Aliment Pharmacol Ther. 2019; 49: 124– 139. 18Shiffman M, Freilich B, Vuppalanchi R, et al. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase activation 3/7 in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019; 49: 64– 73. 19Iacovou M, Craig SS, Yelland GW, Barrett JS, Gibson PR, Muir JG. Randomised clinical trial: reducing the intake of dietary FODMAPs of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet. Aliment Pharmacol Ther. 2018; 48: 1061– 1073. 20Stolz A, Navarro V, Hayashi PH, et al. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther. 2019; 49: 1195– 1204. Volume51, Issue1January 2020Pages 4-5 ReferencesRelatedInformation" @default.
• W4233745237 created "2022-05-12" @default.
• W4233745237 date "2019-12-18" @default.
• W4233745237 modified "2023-09-27" @default.
• W4233745237 title "A Message from the Editors" @default.
• W4233745237 cites W2765875974 @default.
• W4233745237 cites W2766208300 @default.
• W4233745237 cites W2766670674 @default.
• W4233745237 cites W2769703277 @default.
• W4233745237 cites W2772235025 @default.
• W4233745237 cites W2773337546 @default.
• W4233745237 cites W2774116866 @default.
• W4233745237 cites W2774339715 @default.
• W4233745237 cites W2792406291 @default.
• W4233745237 cites W2793923874 @default.
• W4233745237 cites W2896437365 @default.
• W4233745237 cites W2897845166 @default.
• W4233745237 cites W2901189677 @default.
• W4233745237 cites W2906739385 @default.
• W4233745237 cites W2907192638 @default.
• W4233745237 cites W2913931380 @default.
• W4233745237 cites W2922114939 @default.
• W4233745237 cites W2928700601 @default.
• W4233745237 cites W2933615504 @default.
• W4233745237 cites W2954986885 @default.
• W4233745237 doi "https://doi.org/10.1111/apt.15602" @default.
• W4233745237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31850567" @default.
• W4233745237 hasPublicationYear "2019" @default.
• W4233745237 type Work @default.
• W4233745237 citedByCount "0" @default.
• W4233745237 crossrefType "journal-article" @default.
• W4233745237 hasBestOaLocation W42337452371 @default.
• W4233745237 hasConcept C2779473830 @default.
• W4233745237 hasConcept C55493867 @default.
• W4233745237 hasConcept C71924100 @default.
• W4233745237 hasConcept C86803240 @default.
• W4233745237 hasConceptScore W4233745237C2779473830 @default.
• W4233745237 hasConceptScore W4233745237C55493867 @default.
• W4233745237 hasConceptScore W4233745237C71924100 @default.
• W4233745237 hasConceptScore W4233745237C86803240 @default.
• W4233745237 hasIssue "1" @default.
• W4233745237 hasLocation W42337452371 @default.
• W4233745237 hasLocation W42337452372 @default.
• W4233745237 hasOpenAccess W4233745237 @default.
• W4233745237 hasPrimaryLocation W42337452371 @default.
• W4233745237 hasRelatedWork W1506200166 @default.
• W4233745237 hasRelatedWork W1995515455 @default.
• W4233745237 hasRelatedWork W2048182022 @default.
• W4233745237 hasRelatedWork W2080531066 @default.
• W4233745237 hasRelatedWork W2604872355 @default.
• W4233745237 hasRelatedWork W2748952813 @default.
• W4233745237 hasRelatedWork W2899084033 @default.
• W4233745237 hasRelatedWork W3031052312 @default.
• W4233745237 hasRelatedWork W3032375762 @default.
• W4233745237 hasRelatedWork W3108674512 @default.
• W4233745237 hasVolume "51" @default.
• W4233745237 isParatext "false" @default.
• W4233745237 isRetracted "false" @default.
• W4233745237 workType "article" @default.